"Getting it right first time" for children with renal tumours
Improving prediction of relapse, treatment delivery and outcomes for children with renal tumours in the UK
Investigating the genetic pathways that control leukaemia growth
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia
Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
Mapping drug targets in aggressive non-Hodgkin lymphoma
Investigation of potential therapeutic targets in paediatric aggressive B-cell non-Hodgkin lymphoma - towards kinder, more effective treatments
Repurposing existing drugs to improve outcomes in Ewing sarcoma
Repurposing of drugs targeting drug resistant self-renewing Ewing’s sarcoma cells to accelerate new treatments into clinical trials to improve outcomes.
Identifying combinations of repurposed drugs for new treatments of acute myeloid leukaemia
Facing the MuSIC - identification of synergistic repurposed drug combinations as novel therapies in paediatric acute myeloid leukaemia
Understanding the genetics of poor outcome neuroblastoma to improve treatment
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Understanding why some children with neuroblastoma have worse survival or respond badly to treatment
Targeting the Fanconi Anaemia pathyway in neuroblastoma
Understanding drug resistance in neuroblastoma to develop personalised treatments
Overcoming drug resistance for efficacious neuroblastoma therapeutics